Halozyme posts record Q2 2026, raises full-year guidance on royalty growthAug 6Quarterly updateHalozyme Therapeutics
argenx registers Phase 3 trial of adimanebart in rare congenital myasthenic syndromesAug 4Trial updateadimanebartargenx
argenx registers Phase 2a empasiprubart trial in gMG; adimanebart PK study recruitingJun 29Weekly roundup, 2 itemsadimanebartargenx
Sign inSign in